OR WAIT null SECS
Saneca Pharma is making significant investment in its API capabilities to support client demand for smaller batch sizes and streamlined scale-up.
Slovakia-based CDMO Saneca Pharma announced that it is making significant investment in its API capabilities to support client demand for smaller batch sizes and streamlined scale-up. The company is strengthening its infrastructure and expanding its suite of equipment within its five API production units to reinforce its expertise in opiate and synthetic drug development and production.
Saneca Pharma is investing in several smaller reactors for batches of approximately 1 to 30 kg in its new kilo laboratory, which has capabilities such as scale-up and optimization activities that stimulate a large-scale production processes. Operating from a site that has manufactured APIs since 1941, Saneca Pharma develops and manufactures synthetic and bio-mass APIs, especially controlled substances based on morphine and other poppy straw alkaloids. With a dedicated morphine production unit, Saneca Pharma has specialist expertise in opiate API manufacturing, with full supply-chain integration from raw materials to oral and semisolid finished dosage forms.
The CDMO currently manufactures more than 30 different APIs on-site. To simplify the transfer of client projects from pilot to commercial scale, its team uses the same equipment in the API development and manufacturing facilities.